Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.

Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM.

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com...

Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPAT...

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they pro...

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rall...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on th...

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vu...

Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Am...